Inhibitor Therapeutics, Inc.
INTI
$0.0434
-$0.0051-10.52%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.19% | -3.66% | 4.45% | 36.12% | 113.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.20% | 7.41% | 34.87% | 81.84% | 197.30% |
| Operating Income | -0.20% | -7.41% | -34.87% | -81.84% | -197.30% |
| Income Before Tax | -3.66% | -10.34% | -129.22% | -127.09% | -127.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.66% | -10.34% | -129.37% | -127.22% | -127.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.66% | -10.34% | -129.37% | -127.22% | -127.19% |
| EBIT | -0.20% | -7.41% | -34.87% | -81.84% | -197.30% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.24% | -10.23% | -168.58% | -159.26% | -155.72% |
| Normalized Basic EPS | -4.35% | -10.91% | -47.37% | -105.66% | -283.33% |
| EPS Diluted | -3.24% | -10.23% | -176.82% | -165.43% | -160.86% |
| Normalized Diluted EPS | -4.35% | -10.91% | -47.37% | -105.66% | -283.33% |
| Average Basic Shares Outstanding | 0.18% | 0.18% | -18.96% | -34.73% | -45.38% |
| Average Diluted Shares Outstanding | 0.18% | 0.18% | -18.96% | -34.73% | -45.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |